Floatz logo

Paclitaxel Poliglumex

Malignant Ovarian Mixed Epithelial Tumor

GOG FoundationPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Ovarian Mixed Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B
Urokinase-Derived Peptide A6
Gynecologic Oncology Group
Phase 2B
Hycamtin
Gynecologic Oncology Group
Phase 2CCC
FILGRASTIM
Gynecologic Oncology Group
Phase 2CCC
Inno-206
Gynecologic Oncology Group
Phase 1CC
CIS-DIAMMINEDICHLOROPLATINUM II
Gynecologic Oncology Group
Phase 1CC
Vtx-2337
Gynecologic Oncology Group
Phase 1CC

Same molecule, other indications

Paclitaxel Poliglumex is also rated in:

Primary Peritoneal CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Ovarian Undifferentiated CarcinomaDormant
B
Indicative ·
56 / 100
View asset →
Ovarian Brenner TumorDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →